Search results
Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including...
FOX 23 News Albany· 14 hours agoIn the results, olverembatinib showed excellent durable clinical benefits and favorable long-term tolerability in patients who had been treated with multiple TKIs (including those...
Health inequities: How socioeconomic factors affect outcomes for pediatric cancer patients
Medical Xpress· 3 hours agoIt's important for everyone–health care providers, donors, researchers, educators, advocates, and...
"I'm brave and I'm strong": 5-year-old overcomes years of painful cancer treatments
CBS News· 3 hours ago"I'm brave and I'm strong and I can do all things," Arianna says. In July 2020, at 21 months old and...
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials...
Morningstar· 1 day agoFN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83 billion in 2024, and is expected ...
Treatment of Blood Cancers
Digital Journal· 5 hours ago(NYSE American: ATNM). Actinium is a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies. Approximately every 3 minutes, one person in the US ...
EHA 2024: Brukinsa/Venclexta for CLL/SLL lacks control arm in SEQUOIA trial
Clinical Trials Arena via Yahoo Finance· 1 day agoCLL and ...mutation, there is still a need for treatments that provide durable responses and extend...
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
Zacks via Yahoo Finance· 4 days agoShattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute...
EHA 2024: Novartis Scemblix takes on all TKIs in head-to-head CML trial
Clinical Trials Arena via Yahoo Finance· 2 days agoWhile the differences in side effect rates...associated side effects less suitable. Given the...
MD Anderson Research Highlights: EHA 2024 Special | Newswise
Newswise· 6 days agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research, and prevention. Thes
Syndax reports encouraging results from AML treatment trials By Investing.com
Investing.com· 4 days agoSyndax Pharmaceuticals (NASDAQ: NASDAQ:SNDX), a clinical stage biopharmaceutical company, has...
